Related Experiment Video

Updated: Jun 27, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

Re: Residual treatment disparities after oncology referral for rectal cancer

Kathryn M Field, Suzanne Kosmider, Jayesh Desai

    Journal of the National Cancer Institute
    |November 27, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
    06:46

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

    Published on: September 27, 2024

    Related Experiment Videos

    Last Updated: Jun 27, 2026

    Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
    12:45

    Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

    Published on: February 12, 2022

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
    06:46

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

    Published on: September 27, 2024

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer.

    International journal of cancer·2026

    Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

    Cancer·2026

    Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases.

    NPJ precision oncology·2026

    Genomic Therapy Matching in Rare and Refractory Cancers.

    JAMA oncology·2026

    Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.

    NPJ precision oncology·2026

    Associations between breast cancer and rheumatoid arthritis among older-age women in the United States.

    Journal of the National Cancer Institute·2026

    NCI's clinical assay development program: supporting translation of biomarkers for cancer diagnosis.

    Journal of the National Cancer Institute·2026

    Changes In body composition and subsequent risk of relapse In childhood hodgkin lymphoma.

    Journal of the National Cancer Institute·2026

    Trends in bone health agent use and skeletal events in metastatic castration-resistant prostate cancer.

    Journal of the National Cancer Institute·2026

    Risk of second primary malignancies in older long-term survivors of breast, prostate, colon, and rectal cancer.

    Journal of the National Cancer Institute·2026

    Alignment with lifestyle recommendations and physical health in breast cancer survivors and women without cancer.

    Journal of the National Cancer Institute·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us